Immunology and Microbiology
Bispecific Antibody
100%
T Cell
99%
Cancer Cell
73%
Tumor Cell
58%
Monospecific Antibody
44%
Cancer Immunotherapy
36%
Antineoplastic Activity
35%
TNF related apoptosis inducing ligand
32%
CD20
30%
Mouse
26%
Epithelial Cell Adhesion Molecule
26%
CD47
25%
Cytotoxicity
22%
CD3 Antigen
20%
Myeloid
19%
Cell Death
19%
Effector Cell
18%
Monoclonal Antibody
17%
Single-Chain Variable Fragment
17%
Chondroitin Sulfate Proteoglycan
17%
Carcinoma Cell
16%
Cell Surface
16%
Tumor Antigen
16%
Lymphocyte
16%
Target Cell
15%
Glycoprotein
15%
Tumor Necrosis Factor
15%
Agonist
14%
Immunotherapy
14%
Positron Emission Tomography
13%
Inflammatory Arthritis
13%
Xenograft
13%
Antigen Specificity
13%
Bacteriophage
12%
Cytomegalovirus
12%
Ecalectin
12%
Interleukin 13
12%
Immunocompetent Cell
11%
B Cell
11%
Nude Mouse
11%
Rituximab
11%
T Cell Receptor
11%
Immunosuppressive Drug
11%
Epitope
10%
Phage Display
10%
CD40 Ligand
10%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
10%
Adenoviridae
9%
Western Blot
9%
Cell Activation
9%
Medicine and Dentistry
Fusion Protein
87%
Neoplasm
68%
T Cell
54%
Prostate Cancer
48%
Programmed Cell Death
43%
Cancer Cell
39%
Antineoplastic Activity
34%
Tumor Cell
33%
Bispecific Antibody
31%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
30%
In Vitro
30%
Malignant Neoplasm
26%
Epithelial Cell Adhesion Molecule
21%
Gastrin Releasing Peptide Receptor
20%
Carcinoma Cell
20%
Cell Surface
20%
Antigen Specificity
19%
Active Immunotherapy
19%
Ovarian Cancer
19%
Randomized Controlled Trial
19%
Prostate Specific Membrane Antigen
19%
Monoclonal Antibody
17%
Proteochondroitin Sulfate
17%
Cancer Immunotherapy
17%
Single Chain Fragment Variable Antibody
16%
Indium 111
16%
Endothelial Cell
15%
Bombesin
15%
Image-Guided Surgery
15%
Cancer Therapy
14%
Nodular Melanoma
14%
Target Cell
13%
Triple Negative Breast Cancer
13%
Cytomegalovirus
12%
Tau Protein
12%
Temoporfin
12%
Interleukin 13
12%
Gene Therapy
12%
CD20
11%
Adenoviridae
11%
Carcinoma
11%
Cytotoxicity
11%
Epidermal Growth Factor Receptor
10%
Tumor Necrosis Factor
10%
Side Effect
10%
Radioactive Tracer
10%
Positron Emission Tomography
10%
Single Photon Emission Computed Tomography-Computed Tomography
9%
Xenograft
9%
Cell Death
9%
Keyphrases
Bispecific Antibody
20%
Active Immunization
19%
Ovarian Cancer
19%
Antigen-specific
12%
Chondroitin Sulfate Proteoglycans
12%
Randomized Controlled Trial
11%
Immunotoxin
9%
Tumor Cells
9%
Lymphocyte Adhesion
8%
Transendothelial Migration
8%
Pan-carcinoma
7%
Cytolytic Activity
7%
T Cells
7%
Tumor
7%
Interleukin-2
6%
Fusion Protein
6%
Cancer Therapy
6%
Human Cytolytic Fusion Protein
6%
Clinical Efficacy
6%
Targeted Cancer Immunotherapy
6%
Temoporfin
6%
PEGylated PLGA
6%
PLGA Nanoparticles
6%
Cytolytic Fusion Protein
6%
Cancer Cell Death
6%
Hepatic Ischemia-reperfusion Injury
6%
Programmed Cell Death Receptor Ligand 1
6%
Dual-modality
6%
Bifunctional Antibody
6%
Allograft Injury
6%
Intraepithelial T Cells
6%
Apoptosis
6%
Lymphocytes
6%
Acute Kidney
6%
IgG1 Monoclonal Antibody
6%
Human IgG1
6%
Human Head
6%
Comprehensive Complication Index
6%
Human Epidermal Growth Factor Receptor
6%
Immuno-SPECT
6%
Kidney Allograft
6%
Photochemical Internalization
6%
Human Neck
6%
Adenovirus
6%
Apoptosis Induction
6%
Adaptive Immune Resistance
6%
Cargo Delivery
6%
SFasL
6%
Magnetic Resonance Imaging
6%
Mucosal Disease
6%
